Specific Considerations with Cardiac Disease - Valvular Heart Disease

Specific Considerations with Cardiac Disease - Valvular Heart Disease is a topic covered in the Clinical Anesthesia Procedures.

To view the entire topic, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Explore these free sample topics:

Anesthesia Central

-- The first section of this topic is shown below --

Aortic Stenosis

Aortic Stenosis

  1. The etiology is usually progressive calcification and narrowing of a tricuspid or bicuspid valve. A valve area less than 1.0 cm2 or mean gradient greater than 40 mm Hg defines severe stenosis. Mild stenosis is defined as a valve area of greater than 1.5 cm2 or mean gradient of less than 25 mm Hg. Moderate stenosis is defined as a valve area between 1.0 and 1.5 cm2 or a gradient between 25 and 40 mm Hg.
  2. Symptoms of angina, syncope, or heart failure develop late in the disease process. In the absence of surgical intervention, the average survival is 2 to 3 years following the onset of symptoms.
  3. PathophysiologyThe ventricle becomes hypertrophied and stiff in response to the increased pressure load. Coordinated atrial contraction becomes critical to maintaining adequate ventricular filling and stroke volume. The ventricle is susceptible to ischemia due to increased muscle mass and decreased coronary perfusion in the setting of increased intraventricular pressure.
  4. Anesthetic considerations. Aortic stenosis is the only valvular lesion associated with an increased risk of perioperative ischemia, MI, and death.
    1. Normal sinus rhythm and adequate volume status should be maintained.
    2. Avoid systemic hypotension. Hypotension should be treated immediately and aggressively with an α-agonist such as phenylephrine to maintain adequate coronary perfusion pressure.
    3. Avoid tachycardia. Tachycardia results in increased oxygen demand along with a shorter period of diastole leading to decreased coronary perfusion and reduced cardiac output. Severe bradycardia can lead to reduced cardiac output and should be avoided as well. Cardiac pacing capabilities should be considered to treat severe bradycardia. Supraventricular tachydysrhythmias should be treated aggressively with direct current cardioversion.
    4. Nitrates and peripheral vasodilators should be administered with extreme caution.
    5. The treatment of ischemia in these patients is directed at increasing oxygen delivery by raising coronary perfusion pressure and decreasing oxygen consumption (by increasing blood pressure and lowering heart rate).

-- To view the remaining sections of this topic, please or purchase a subscription --


* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Specific Considerations with Cardiac Disease - Valvular Heart Disease ID - 728468 Y1 - 2019 PB - Clinical Anesthesia Procedures UR - https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728468/all/Specific_Considerations_with_Cardiac_Disease___Valvular_Heart_Disease ER -